iBio, Inc.
IBIO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $400 | $225 | $0 | $1,884 |
| % Growth | 77.8% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3,791 |
| Gross Profit | $400 | $225 | $0 | -$1,907 |
| % Margin | 100% | 100% | – | -101.2% |
| R&D Expenses | $8,312 | $5,185 | $10,327 | $9,827 |
| G&A Expenses | $10,690 | $11,674 | $19,016 | $0 |
| SG&A Expenses | $10,690 | $11,674 | $19,016 | $17,963 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,002 | $16,859 | $29,343 | $27,790 |
| Operating Income | -$18,602 | -$16,634 | -$29,343 | -$29,697 |
| % Margin | -4,650.5% | -7,392.9% | – | -1,576.3% |
| Other Income/Exp. Net | $225 | $1,191 | $32 | $184 |
| Pre-Tax Income | -$18,377 | -$15,443 | -$29,311 | -$29,513 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18,377 | -$24,907 | -$65,010 | -$50,391 |
| % Margin | -4,594.3% | -11,069.8% | – | -2,674.7% |
| EPS | -1.75 | -6.5 | -23.94 | -58.49 |
| % Growth | 73.1% | 72.8% | 59.1% | – |
| EPS Diluted | -1.75 | -6.5 | -23.94 | -58.49 |
| Weighted Avg Shares Out | 10,499 | 3,831 | 1,225 | 872 |
| Weighted Avg Shares Out Dil | 10,499 | 3,831 | 1,225 | 872 |
| Supplemental Information | – | – | – | – |
| Interest Income | $437 | $363 | $130 | $177 |
| Interest Expense | $212 | $172 | $0 | $0 |
| Depreciation & Amortization | $1,126 | $1,250 | $1,380 | $3,791 |
| EBITDA | -$17,039 | -$14,021 | -$27,848 | -$25,722 |
| % Margin | -4,259.8% | -6,231.6% | – | -1,365.3% |